hitch ride cancer research growth initi
outperform pt
initi coverag outperform rate pt view
well posit benefit secular growth trend oncolog drug
develop expect compani solidifi posit prefer provid
genet test servic pharmaceut client base channel check
suggest high level custom support matur landscap requir
complex diagnost test upsid clinic trial person neoantigen
product build brand base qualiti breadth menu view
incent pharma compani switch vendor low result sticki
relationship last expect near-term growth acceler base launch
immunoid offer
best-in-class test model pharma unlik diagnost compani
provid test clinic market fulli commit
optim product drug compani convers pharma custom
qualiti consist rank import consider select
believ focu brand equiti translat signific
healthi end growth cancer drug estim number
cancer drug clinic studi increas expect
sustain growth significantli trend base pharma consolid
limit group vendor ex-u growth commerci organ
potenti enter commerci product person neoantigen product
potenti upsid neoantigen vaccin person neoantigen vaccin
requir rapid turnaround time day low test failur rate broad mutat
coverag domin posit high-valu nich
revenu per sampl posit take advantag futur growth
larger clinic trial potenti commerci sale
product cycl acceler growth expect introduct immunoid
solidifi relationship exist custom expand
rang potenti project current client gain foothold drug
compani seek singl vendor handl full rang test
reimburs psnl busi pharmaceut
compani fix rate govern contract believ offer
safe potenti headwind relat futur pama discuss broader
us healthcar reform chang medicar coverag ngs-base test
year price histori
provid test servic
pharmaceut compani primarili
platform offer variant analysi
gene also offer
hla msi-rel
often import immun
oncolog research compani
provid clinic test
analyst certif import disclosur see disclosur
launch immunoid broader test menu result
acceler test sampl pharmaceut custom
begin
liquid biopsi gain accept sourc addit genet
inform replac tissue-bas test primari
modal cancer research
person neoantigen vaccin remain import area
clinic develop product approv next year
va deliv enough sampl recogn full valu contract
end
view proxi continu growth pharmaceut
immun oncolog research budget differenti base
complet focu corpor govern custom
clinic test view focu key asset
support premium product offer emphas qualiti
sequenc result flexibl menu base discuss
custom believ focu qualiti establish
power brand oncolog research given modest cost
diagnost test total drug develop budget
view market price sensit expect high level
custom sticki
introduct immunoid beta site broader
commerci introduct
formal annual renew activ va contract
launch clinic diagnost pharmaceut custom
introduct liquid biopsi product supplement tissue-
va expand extend million veteran program program
result potenti upsid financi outlook long
person neoantigen vaccin success commerci
offer potenti support commerci sale addit larg
invest ex us commerci organ allow
captur larger portion total research budget exist global
outlook base sole organ growth bolt-on acquisit
could offer upsid revenu forecast
va fail deliv expect number sampl result
shortfal expect revenu
liquid biopsi gain accept altern tissue-bas
test undercut tradit strength tissue-bas
person neoantigen vaccin fail demonstr benefit
clinic develop result declin demand one
highest valu segment busi
pace success innov immun oncolog slow result
deceler growth oncolog drug discoveri budget
pt base price-to-sal analysi assum multipl estim revenu million share
outstand discount back one year line peer group high-growth diagnost compani multipl around
risk includ new product adopt includ introduct immunoid platform custom concentr
relat va contract two commerci custom exceed revenu us govern fund procur process
may impact futur activ va contract lesser extent pharmaceut research activ fund nih grant
technolog obsolesc relat current relianc tissue-bas test clinic trial includ early-stag clinic trial
novel person neoantigen vaccin high level sharehold concentr among three ventur investor
initi outperform pt
initi coverag personali inc outperform rate price
target view well posit benefit secular growth trend oncolog
drug develop expect compani solidifi posit prefer provid
genet test servic pharmaceut client base channel check suggest
high level custom support base superior qualiti genet test custom
servic matur immune-oncolog drug develop landscap requir
complex diagnost test capabl discoveri research signific potenti
upsid clinic trial person neoantigen product requir
diagnost test per patient term sustain psnl competit
posit view foundat medicin part roch offer
instruct compar base recognit differ test need pharmaceut
compani vs clinic market build brand base qualiti breadth menu
view incent pharma compani switch vendor low result
sticki relationship pt base price-to-sal analysi assum
multipl estim revenu discount back month
million share outstand
genet test pharma differ clinic market
unlik everi compani diagnost coverag univers provid
test clinic set rather fulli commit optim test servic
drug compani domin focu oncolog drug develop compani
foundat medicin mix pharmaceut clinic custom
howev view core product compani defin need larger
clinic market limit number gene competit price convers
pharma custom qualiti consist rank import consider
select definit qualiti vari somewhat believ
custom describ abil provid data given sampl
provid flexibl test option psnl immunoid platform offer coverag
gene vs competitor adequ depth sequenc support
low no-cal rate flexibl servic model allow custom menu
test option price rare highlight top two consider custom
believ technolog intellectu properti barrier anoth compani
replic psnl model compani reput grow economi scale
formid competit advantag view
ride secular growth trend immun oncolog drug develop
addit two custom disclos merck
due dilig suggest compani also grow relationship sever larg
biotech compani oncolog space nearli compani work
burgeon field person neoantigen vaccin total compani least
oncology-focus custom view share one
cleanest proxi particip gener growth cancer drug research
awar reliabl statist pace growth pharmaceut spend
cancer research view growth number immun oncolog drug clinic
trial good proxi base data cancer research institut estim
number drug increas expect sustain growth significantli
trend base prefer pharma compani consolid
relationship limit group vendor potenti expand market share outsid
us ex us divis global compani potenti enter nich
commerci test market product person neoantigen product
product cycl drive acceler growth
expect begin introduct immunoid product
aggress roll-out product expans compani exist ace
immunoid platform addit function includ oncoviru analysi
immunocellular deconvolut expect enhanc solidifi relationship
exist custom expand rang potenti project current client
gain foothold drug compani seek singl vendor handl full rang
test expect roll-out immunoid accompani expans
sale organ includ focu ex us market net
expect invest acceler non-va growth
differenti take base coverag neoantigen biotech
therapeut view provid uniqu insight growth prospect
import market mention person neoantigen vaccin
requir rapid turnaround time day low test failur rate broad mutat
coverag domin posit high-valu nich posit take
advantag futur growth larger clinic trial potenti commerci
sale base discuss sever neoantigen custom believ
compani made strateg decis work contract manufactur
organ cmo base potenti acceler time-to-ind third parti
contractor prefer alloc capit prior proof concept clinic trial
rather intern manufactur infrastructur opportun flexibl
chang adapt protocol first-in-class peptide-bas neoantigen product
view small grow neoantigen compani among psnl
stickiest custom segment grow faster rate total revenu
next year
reimburs medicar commerci payer risk
clinic diagnost compani face persist price headwind medicar
insur compani psnl busi pharmaceut compani
fix rate govern contract believ offer safe
reimburs headwind relat futur pama discuss broader us healthcar
reform chang medicar coverag next-generation-sequenc -base
one challeng valu high growth clinic diagnost compani
risk/opportun futur acquisit expand new
market distribut channel believ growth acquisit
merit support top-lin growth strategi often lead serial issuanc common
stock given psnl singular focu pharmaceut market view bolt-on
acquisit offer access differ distribut channel unlik make sens
exclud possibl bolt-on technolog deal current see limit
need beyond perhap liquid biopsi expect remain focus
capit effici intern growth move outsid pharmaceut channel
view like done sale compani acquisit
price target share base primarili price-to-sal multipl
project revenu discount back month view price-to-sal
appropri methodolog compani transit sustain profit
common valuat metric diagnost test compani
mention view uniqu busi model due compani
total focu pharmaceut custom awar directli compar
publicli trade cancer test lab foundat medicin part roch probabl
offer closest compar offer similar
growth outlook focu oncolog expos signific clinic
reimburs headwind view offer dramat differ risk profil
addit includ guardant analysi base
compani abil expand establish market offer innov valu
proposit highlight exhibit specialti test oncolog lab
trade multipl sale given psnl higher growth rate believ stock
deserv modest premium peer group
exhibit ev-to-sal peer group analysi
factset oppenheim co inc estim factset estim non-cov compani gh lh
use base year price-to-sal analysi base expect
need month fulli captur growth potenti immunoid
product introduct expand us sale forc invest growth opportun
outsid us
last view discount rate appropri given compani
enough cash fund oper profit
sale price-to-sal period share count share fair revenuerevenuecash markettech ev/price/segmenttickercompani estequiv ltdvalu ev/g fischer pro forma post-deal balanc repres equiti market valu plu long-term debt less ep base fiscal year ev-to-sal divid revenu growth high growth diagnost larg refer lab legaci genet test larg sequenc compani personali inc
view share like primarili quarterli revenu growth stori
next month disclosur quarterli financi offer import
catalyst term oper updat focus new product introduct
includ launch immunoid beta site late broader commerci
roll-out expect term catalyst view launch liquid biopsi
assay uptak compani clinic diagnost sold pharmaceut
compani clinic trial two import new product offer
oppenheim co inc estim compani document
septemb psnl contract va subject annual renew
see littl risk modif work plan view formal extens
agreement de-risk event last expir compani current leas
laboratori space menlo park expect manag explor opportun
addit space support long term growth
corpor histori busi model
form februari use novel sequenc sampl prep
bioinformat provid better gene coverag particularli complex sampl
limit dna compani launch first exosom test gene
cancer panel addit evolv servic offer includ
post-analyt identif biomark particularli analyz neoantigen
select sequenc whole genom million veteran
program mvp contract valu
corpor headquart includ clia-certifi cap-accredit laboratori
locat menlo park ca compani rais roughli three ventur capit
round led lightspe ventur partner abingworth complet ipo
stock exchang ticker june gener net
proce classifi sec emerg growth compani
focus captur domin market share high-perform premium-
price segment genet test market open pay broader
gene coverag deeper sequenc certain portion genom conjunct
provid premium product invest provid high level
custom servic hire commerci personnel extens technic
experi invest client interfac symphoni allow real time monitor
workflow flexibl test menu option support custom custom
practic primari market comprehens test servic pharmaceut
compani certain govern agenc provid test clinic
market base review competit landscap believ
compani focus sole pharmaceut industri compani foundat
medicin mix pharmaceut clinic custom howev view
core product compani defin need larger clinic market limit
number gene competit price convers pharma custom
qualiti consist rank import consider select
definit qualiti vari somewhat believ custom describ
eventtim importancecontract renew decis va mvp immunoid liquid biopsi assay move hq expand manufactur outperform
abil provid data given sampl provid flexibl test option
psnl immunoid platform offer coverag gene vs
competitor adequ depth sequenc support low no-cal rate flexibl
servic model allow custom menu test option price rare
highlight top two consider custom believ
technolog intellectu properti barrier anoth compani replic psnl model
view compani reput grow economi scale formid
prior commerci first checkpoint inhibitor begin yervoy
view oncolog drug develop attract amalgam nich market
primarili domain small biotech startup commerci success
inhibitor keytruda opdivo nearli everi larg pharmaceut compani
commit aggress expans oncolog research furthermor support capit
market expand access capit biotech start-up level previous
experienc sector
take introduct checkpoint inhibitor result rapid expans oncolog
drug discoveri budget creat viabl market pharma-onli genet test
compani form enjoy first-mov advantag pharma-
busi model
net global sale cancer therapeut drug nearli doubl
increas accord market research group iqvia see exhibit
exhibit spend cancer drug doubl
iqvia global trend oncolog
sale top nine fda-approv immuno-oncolog drug gener revenu
nearli period attribut inhibitor see exhibit
parallel increas revenu pharma compani fund
dramat expans clinic trial explor addit solid tumor type may
benefit monotherapi explor combin regimen
immun oncolog drug chemotherapi
exhibit sharp rise immun oncolog sale driven checkpoint inhibitor
iqvia deal trend immuno-oncolog
highlight exhibit total number clinical-
stage organ non-profit academ commerci increas
also number immun oncolog drug develop increas
importantli mani immuno-oncolog drug requir
complex ngs-base test compar prior gener kinase-bas target
therapi often requir use pcr test
take expect futur oncolog drug develop shift toward find therapi
treat patient respond inhibitor monotherapi expect
drug develop combin regimen requir complex genet test
understand potenti contribut product
exhibit growth number immun oncolog drug develop
adapt cancer research institut report
cell therapy/car-t immunomodulatori agent cancer vaccin
common class new agent exhibit
exhibit growth new compound spread across differ modal
tang et al cancer research institut trend global immuno-oncolog landscap natur review drug discoveri
take multipl growth driver immun oncolog drug sale pipelin
expans group well posit sustain growth least next
year pipelin matur requir larg late stage clinic trial
result drug continu annual expens well base
data immuno-oncolog clinic trial globaldata estim
compound-annual-growth-rate compound annual growth rate immuno-oncolog clinic trial
believ reason estim base interest immuno-oncolog
realli taken last five year
role diagnost genom medicin
past five year cost next-gener sequenc technolog rapidli
declin result potenti use wider rang applic one end
spectrum target sequenc limit number gene done quickli
support clinic grade patient-initi hereditari cancer screen
use lower cost sequenc tool creat new clinic consum market
expand use genet test establish busi model view
believ mani investor overlook impact lower sequenc cost
pharmaceut mention oncolog market overview number
new drug candid enter develop genet defin diseas
cancer also accler least part due lower cost broader applic
sequenc one compani correctli identifi second trend
establish servic offer serv need pharmaceut research
includ need analyz much broader set gene
provid overview gener concept
whole exom sequenc effici method evalu medic import
variant exom compris exon associ protein-cod gene although
exom make genom human includ approxim
medic interpret genom
compar polymeras chain reaction pcr sanger sequenc exom sequenc
effici detect somat mutat unbias analysi single-bas
mutat altern tool polymeras chain reaction pcr sanger
sequenc howev whole exom sequenc often lack accuraci tradit
sequenc method particularli problemat drug research improv
accur either sampl prepar bioinformat interpret enhanc
qualiti result
take carv nich within diagnost industri focus high-
qualiti result better accuraci across gene
whole exom sequenc divid three gener step librari prep sequenc
data analysi equip sold industri standard
primarili use
librari prepar bioinformat standard primari avenu
avail servic provid either improv accuraci reduc cost exibit
overview whole exom sequenc work flow
applic whole exom sequenc identifi disease-caus variant inherit diseas genom
broadli librari prep consist collect genom dna gdna shear cell
tail gdna blunt end datp ligat gdna adaptor follow
librari prep gdna hybrid array target probe sequenc also known
base call provid raw data consist nucleotid read inform need
process bioinformat consist three step process
read align variant call
take proprietari aspect technolog librari prep data
psnl differenti base ace assay
psnl tissue-bas test liquid biopsi product incorpor compani
content enhanc ace assay primari basi coverag
gene better qualiti result competitor process cover issu
patent us view import sourc differenti
perform benefit ace describ two review articl compar
perform differ methodolog articl publish genom medicin
entitl achiev high-sensit clinic applic use augment
exom sequenc scientist describ ace assay method provid
thorough coverag difficult sequenc region gc content redund
paralog repetit content breakpoint librari region area repeat collaps
address variabl region scientist develop target probe
enhanc captur effici gene criteria gene consid
medic relev associ monogen diseas implic
pharmacolog interfer regul signal pathway close link
diseas process cancer defin intern collabor clinic
genom iccg includ addit gene interest non-cod region
genom regul express protein utr intergen intron
patwardhan et al achiev high-sensit clinic applic use augment exom sequenc genom
total gene identifi number open-sourc genom
databas human gene mutat databas hgmd on-line mendelian omim
genet test registri gtr cancer gene consensu cosmic pharmgkb
remain gene identifi select public enhanc
captur target dna pool target dna captur standard enrich
use sscr kit exhibit
accuraci sequenc data often determin coverag metric
minimum coverag threshold research-qu sequenc data coverag
defin number align read contain given nucleotid posit error rate
invers proport coverag depth
qualiti metric includ analyt sensit percentag target base
repres one sequenc read analyt specif percentag
sequenc map intend target region exhibit highlight ace
offer better coverag compet assay
exhibit coverag effici code region platform
patwardhan et al achiev high-sensit clinic applic use augment exom sequenc genom
specif ace assay achiev threshold minimum coverag
base protein-cod region base non-protein-
code region peer group assay includ agil sureselect clinic research
exom enrich nx nimblegen seqcap ez ng human exom librari
achiev rang protein-cod region non-protein-cod
importantli use ace platform assay finish exon compar
platform finish exon defin base coverag coverag
specif convent whole exom sequenc platform sscr ss nx ng
finish exon see exhibit
exhibit ace achiev higher percentag finish exon
patwardhan et al achiev high-sensit clinic applic use augment exom sequenc genom
net perform benefit ace allow fill gap coverag associ
standard exom captur kit sscr exhibit graphic provid
overview gap fill ace blue area adequ cover
psnl bioinformat enabl broader menu launch
bioinformat tool use align read refer exom analyz
differ sampl exom refer exom use standard
softwar process raw sequenc data read fastq format analyz
phred-scal qualiti score cluster read first align burrows-wheel
align picard softwar follow base qualiti score sequenc
align via genom analysi toolkit gatk
also use unifi genotyp modul gatk call variant way
background four main class variant singl nucleotid variant snv
insert delet indel copi number variant cnv structur variant
sv variant class requir distinct comput capac also
introduc modular menu immune-specif analyt call immunoid
identifi classifi variant function class
expect begin introduct immunoid product
aggress roll-out product expans compani exist ace
immunoid platform addit function includ oncoviru analysi
immunocellular deconvolut expect enhanc solidifi relationship
exist custom expand rang potenti project current client
gain foothold drug compani seek singl vendor handl full rang
platform offer sever stepwis improv includ enhanc analysi
ace gene vs prior gener improv depth coverag
better base call somat mutat immun repertoir analysi may
support use platform monitor treatment-rel chang tumor
take immun repertoir analysi offer biggest near-term enhanc
may support expand use immunoid serial test clinic studi
rather one-off analysi prior studi
repertoireid survey repertoir cell multipl function
immun system regul recognit peptid
neoantigenid provid detail identif neoantigen machine-
may announc formerli known flx
first publicli disclos beta custom immunoid use platform
phase i/ii studi alon combin pembrolizumab
repertoireidtcr clonal nucleotid amino acid sequencesclonotyp quantit distribut frequencyv gene segment usag nucleotid sequenc lengthimmunogenomicsidhuman leukocyt antigen hla immun modulatorsmicrosatellit instabl dna repair replicationtumor-associ antigen taa adapt innat immun respons cytoxicitycytokin chemokinesantigen process machineri apm neoantigenidantigen identif phase indel fusion major histocompat complex mhc bind predict class ii similar known antigen similar selfimmunogen personali inc
treatment solid tumor investig plan use immunoid monitor
treatment-rel chang tumor miroenviron includ inflammation-rel
immun cell type-rel biomark pre-studi post-treat tumor biopsi
sampl top-lin data expect begin
take view studi potenti early-cas studi valu
immunoid monitor respons therapi may help acceler broader
adopt platform
view uniqu busi model due compani total focu
pharmaceut custom awar directli compar publicli trade
cancer test lab howev believ number compani compet
segment psnl portfolio highlight foundat medicin
medgenom person genom diagnost foundat medicin part
roch probabl offer closest compar view
mention view competit pharmaceut segment base
reput qualiti sequenc data bioinformat analysi turnaround time
menu services/breadth coverag view price secondari
consider custom
foundat medicin subsidiari roch hold
foundat medicin found first compani move
aggress provid high grade tissue-bas sequenc servic
pharmaceut custom clinic care compani success leverag
first mover advantag achiev lead market share clinic test
foundationon product line remain strong competitor pharmaceut
channel particularli clinic trial
foundat offer one fda-approv medicar reimburs test foundationon
cdx two complementari diagnost test foundationon liquid foundationon
heme foundationon cdx analyz gene fda approv provid
tmb somat variant inform solid tumor foundationon liquid
ctdna-bas liquid biopsi test provid target gene data help
direct therapi regimen clinic trial drug combin foundationon heme
comprehens genom profil assay similar foundationonecdx design
hematolog malign foundat record revenu
biopharmaceut compani june roch hold acquir
provid blood-bas liquid biopsi diagnosi cancer monitor
drug respons potenti cancer screen launch
focu primarili gene relev cancer clinic care defin
nation comprehens cancer network test turnaround time
importantli guardant done better job liquid biopsi compani
valid concord blood-bas tissue-bas test view
nile studi prospect head-to-head studi compar efficaci
vs standard tissu biopsi identifi nsclc biomark demonstr
faster turnaround time day day detect biomark patient
patient vs standard tissu biopsi
take guardantomni primari competitor psnl futur liquid biopsi
product expect differenti base breadth gene coverag
guardant introduc guardantomni expand panel gene
test target retrospect sampl analysi patient screen clinic trial
person genom diagnost pgdx offer whole exom sequenc servic
biomark analysi research biopharma market pgdx sell
tissu biopsi requir target analysi test detect snv
indel amplif transloc gene associ cancer
cancerxom immunoselect indic research use provid
inform approxim gene immunoselect use primarili
neoantigen predict liquid biopsi pgdx offer w/msi
identifi common mutat variant similar offer
cancer gene view privat held pgdx direct competitor
medgenom privat bioinformat compani focus immune-oncolog test
within immune-oncolog solut divis medgenom sell tumor
microenviron neo-epitop tcr repertoir analysi product compani also
market somat cancer mutat profil product base discuss biotech
compani medgenom appear signific reach outsid us
current direct competitor us contract view
neoantigen offer attract target oncolog drug develop base specif
cancer cell may limit off-target advers event rel durabl base
sustain presenc cancer cell neoantigen research gener broken
two segment person autolog therapi select subset
immunogen neoantigen patient tumor share neoantigen seek
build learn person therapi identifi one neoantigen
common specif cancer histolog subpopul
gener form neoantigen byproduct genet mutat present
cell receptor tcr major histocompat complex mhc cancer neoantigen
primarili peptid associ breakdown protein produc oncogen
genet mutat peptid often present surfac cancer cell
induc bind tcr surfac cell primari mechan
healthi immun system recogn tumor cell foreign target cell-
genet mutat may produc protein break multipl differ peptid
singl genet mutat may produc one neoantigen creat two
distinct strategi drug develop deliv neoantigen either boost
immun respons immun system recogn partial subgroup peptid
associ mutat ad neoantigen increas immun respons
de novo respons target previous recogn immun system
limit neoantigen therapi peptid associ tumor present
high level healthi tissu compani develop autolog neoantigen product hope
limit develop peripher toler strategi similar signal-to-nois
principl use diagnost develop much immunolog nois
associ neoantigen express non-canc tissu signal
immun system recogn neoantigen foreign diminish
sever paper demonstr peptide- rna-bas neoantigen elicit broad
immunogen respons neoantigen gener measur cell
respons preclin data translat compar vivo immun respons
tumor microenviron view therapi combin autolog neoantigen
product checkpoint inhibitor potenti improv respons rate
durabl respons way background clinic respons rate checkpoint
inhibitor monotherapi vari cancer type melanoma around
nsclc bladder cancer low singl digit colorect cancer strategi
broaden deepen respons rate need view
poster present meet entitl support neoantigen
augment enhanc ace transcriptom present import valid
use ace improv neoantigen identif specif report analyt
sensit singl nucleotid variant posit predic accuraci
small variant minor allel frequenc fusion event analyt
sensit detect fusion event support least
exhibit list mani compani neoantigen product develop
person vaccin so-cal off-the-shelf product mention
exhibit overview select neoantigen develop program
take person neoantigen vaccin still earli develop
signific clinic develop risk product requir extens diagnost
character per sampl vaccin repres import avenu
potenti upsid revenu outlook
process identifi develop neoantigen cancer vaccin describ
three gener step collect tumor normal tissu sampl identif
neoantigen via formul product vaccin process
summar detail exhibit
aurisicchio et al perfect person cancer therapi cancer vaccin neoantigen journal
va agreementfast path economi scale
view compani agreement veteran administr
strateg asset typic commerci relationship specif view contract
essenti allow achiev appropri economi scale recogn
commerci margin sequenc broad exom panel offer flexibl
turnaround time slot analysi commerci sampl flexibl
allow significantli expand revenu rel modest expans
term va agreement
va million veteran program mvp project complet whole genom
sequenc million veteran term agreement
contain option annual renew sequenc addit
thousand sampl maximum contract valu compani alreadi
recogn potenti receiv addit
va mvp may termin contract sole conveni time
paid percentag contract price reflect portion task complet
reimburs reason loss result termin
agreement strictli contract servicesth va retain sole ownership
access genet inform sampl subject confidenti
partnership acceler time market
premium servic provid view must continu evolv test
menu provid differenti offer custom much innov
support psnl intern team view partnership
academ group select technolog vendor continu import
addit acceler time-to-market new test option view
agreement scientif thought leader may posit psnl new product includ
immunoid rapid valid within larger scientif commun
parker institut immunotherapi cancer research institut
form tumor neoantigen select allianc tesla consortium acceler
cancer biomark tumor antigen research activ member
consortium includ neoantigen research group specif
industri partner within group provid cancer immunogenom platform
includ immunoid studi immunotherapi biomark
take tumor neoantigen select allianc consortium may offer import
network refin immunoid potenti beta site earli commerci roll-out
like genet test lab use sequenc technolog whole
genom exom analysi secur earli access new gener illumina
technolog competit price consum reagent import maintain
psnl posit premium servic provid view
purchas five instrument march sign letter
intent march acquir addit five instrument one deliv
addit compani master servic agreement suppli
reagent expir august
separ novemb subcontract perform certain
genotyp servic va contract
one largest dna sequenc lab us capac process
human sampl annual foot lab hous menlo park
leas expir
lab clia-certifi cap-accredit psnl lab consid high-complex
clinic laboratori improv amend standard subject facil
addit requir ensur accuraci precis specif sensit lab
subject bi-annu survey unannounc inspect clia guidelin
state may adopt stricter laboratori regul mandat feder law
addit maintain california state laboratori licens receiv new
take option renew leas lab three year
move new facil room expand eventu necessari
lab includ high-throughput sequenc system
data storag unit cpu unit tape archiv lab current oper
everi day hour coverag per day
bioinformat import part psnl differenti base high-qual
analysi superior custom servic compani use proprietari informat
inform manag system bioinformat system symphoni connect
laboratori oper downstream data analysi platform also client
interfac allow commun project progress directli client
take step improv turnaround time may requir new automation-system
infrastructur addit introduct liquid biopsi may also requir separ
infrastructur collect initi suggest near-term need space
clinic diagnost compani face persist price headwind medicar
insur compani psnl busi pharmaceut compani
fix rate govern contract chang interpret pama
protect access medicar act potenti reimburs headwind
diagnost test sector impact compani outlook
take offer safe reimburs headwind relat futur
pama discuss broader us healthcar reform chang medicar coverag
term va contract fund us contract requir complet two
separ process first fund need author request propos
rfp contract process addit specif fund amount need
alloc procur budget approv congress believ current
procur level fund contract least actual spend level
often fall short procur level design work plan complet
case psnl va contract rate-limit step futur revenu time
deliveri sampl va view
us suprem court rule associ molecular patholog myriad
genet effect invalid block patent test
germlin variant associ increas hereditari risk ovarian cancer
aggress invas breast cancer wake rule view block patent
protect diagnost product viabl us caveat
take expect differenti genet test increas base custom
experi turnaround time test accuraci brand breadth test menu
price believ know-how form softwar algorithm informat drive
differenti metric
view broad patent protect sustain narrowli draft applic
describ specif method appli technolog may prevent potenti competitor
directli copi psnl analyt method includ ace assay technolog
specif may file us ex-u patent expir
group claim four categori ace assay
technolog hybrid exome-genom technolog liquid biopsi method
base review us file patent entitl method system
genom analysi expir august appear relev patent
appear describ least method incorpor ace
test construct describ workflow psnl neoantigen analysi
expect compani incur addit futur oper loss
achiev profit may gener addit tax asset off-set futur tax
oblig base financi project expect tax asset off-set
first year profit least subsequ period expect
compani recogn effect tax rate
decemb feder net oper loss
carryforward state net oper loss
note believ psnl financi among least transpar forecast
diagnost industri revenu va like volatil depend
number sampl receiv quarter furthermor oncolog research
develop budget larg pharmaceut compani public
inform make gaug chang commerci market demand psnl
commerci test servic difficult project compani track backlog
futur busi expect regularli disclos backlog metric
furthermor given sensit pharmaceut custom disclosur contract
